摘要
目的检测趋化因子5（CXCL5）在胃癌中的表达,探讨其表达与病人临床病理特征和生存的关系。方法收集104例胃癌组织标本及其临床病例资料,采用免疫组织化学（IHC）检测胃癌组织中 CXCL5的表达。染色后阅片评分,采用卡方检验、Log-rank、Kaplan-Meier、Cox 回归模型分析 CXCL5的表达与临床病例特征和胃癌病人预后之间的关系。结果IHC 结果显示104例胃癌标本中有45例（43.2%）CXCL5高表达,癌组织中 CXCL5高表达与胃癌病人的 TNM 分期呈正相关（P=0.007）,CXCL5高表达组病人预后显著低于其低表达组,5年生存率分别为28.7%和62.8%（P 〈0.001）,Cox 回归模型发现 CXCL5的表达是胃癌病人的独立预后因素之一（HR=2.280,CI：1.301-3.998,P =0.004）。结论CXCL5是影响胃癌病人预后的独立因素,可能与胃癌的进展有关。
Objective To evaluate the CXCL5 expression and its prognostic role in gastric canc-er.Methods The expression of CXCL5 in gastric cancer was detected by immunohistochemistry （IHC）.And association between the expression of CXCL5 and clinicopathological characteristics was analyzed among 104 gastric cancer patients.Results The expression of CXCL5 was detected in 45 ca-ses （43.2%）.CXCL5 expression was significantly associated with TNM stage （P =0.007）.Overall survival in low CXCL5 expression group was significantly higher than that in the high CXCL5 expres-sion group （62.8% vs 28.7%,P 〈0.01 ）.CXCL5 expression was an independent prognostic factor according to multivariable Cox-regression survival analysis （HR = 2.280,CI：1 .301 - 3.998;P =0.004）.Conclusions CXCL5 may be a predictive prognostic biomarker for gastric cancer.And it has probably important roles in the development of gastric cancer.
出处
《腹部外科》
2015年第1期28-31,I0001,共5页
Journal of Abdominal Surgery
基金
国家自然科学基金（No.81272643,81272637）
